Related Experiment Videos
Cardiotoxicity of chemotherapy
1Department of Medicine, Institut Gustave Roussy, Savigny-Le-Temple, France.
Current Opinion in Oncology
|July 1, 1994
Summary
Intensified chemotherapy, aided by hematologic support, increases nonhematologic toxicities like cardiotoxicity. Research focuses on understanding drug-induced cardiotoxicity and developing cardioprotective strategies.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Hematologic support enables more intensive chemotherapy regimens, including higher doses and multidrug combinations.
- Increased chemotherapy intensity leads to dose-limiting nonhematologic toxicities, with cardiotoxicity being a significant concern.
- The range of chemotherapeutic agents causing cardiotoxicity is expanding, each with a unique toxicity profile.
Purpose of the Study:
- To investigate the physiopathology of drug-induced cardiotoxicity.
- To characterize agents involved in cardiotoxicity.
- To explore strategies for assessing risk factors and mitigating cardiotoxicity.
Main Methods:
- Review of experimental and clinical research on drug-induced cardiotoxicity.
- Analysis of cardiotoxicity profiles of specific agents like anthracyclines and 5-fluorouracil.
- Exploration of cardioprotective agents and other means to prevent or manage cardiotoxicity.
Main Results:
- Understanding the mechanisms of cardiotoxicity is crucial for managing intensive chemotherapy.
- Specific drug classes, such as anthracyclines and 5-fluorouracil, present distinct cardiotoxicity challenges.
- Research is actively pursuing methods to predict, prevent, and treat chemotherapy-induced cardiotoxicity.
Conclusions:
- Intensified chemotherapy necessitates a thorough understanding of cardiotoxicity.
- Developing effective cardioprotective strategies is essential for patient safety in oncology.
- Ongoing research aims to minimize the cardiac risks associated with cancer treatment.